BCB Bancorp | 10-Q: FY2025 Q3 Revenue: USD 45.79 M

BCB Bancorp, Inc. (NJ) (NASDAQ:BCBP) Share Price Crosses Below 200-Day Moving Average - Should You Sell?

BCB Bancorp, Inc. (NJ) shares fell below their 200-day moving average of $8.44, trading at $7.77. Analysts have mixed ratings, with Zacks upgrading to "hold" and Weiss maintaining a "sell". The company reported Q3 earnings of $0.22 per share, exceeding estimates, and announced a quarterly dividend of $0.16, yielding 8.2%. Institutional investors hold 36% of the stock. The average price target is $9.25, with a consensus rating of "reduce."

U.S. RESEARCH ROUNDUP- BCB Bancorp, Cadence Design Systems, Intellia Therapeutics

Wall Street analysts have updated their ratings and price targets for several U.S.-listed companies. BCB Bancorp's target price was cut to $9 by KBW, while Cadence Design Systems saw an increase to $405 from JP Morgan. Intellia Therapeutics was downgraded by RBC to sector perform with a target price reduction to $14. Other notable changes include target price increases for Ameren Corp, American Airlines, and Mohawk Industries, among others, reflecting a mix of upgrades and downgrades across various sectors.

BCB Bancorp | 8-K: FY2025 Q3 Revenue: USD 45.79 M

BCB Bancorp Q3 net income falls 36%, but interest margins rise

BCB Bancorp reported a 36% decline in Q3 net income, falling to $4.3 million from $6.7 million a year earlier. Earnings per share (EPS) dropped to $0.22 from $0.36. However, the net interest margin improved to 2.88%, up from 2.58% due to lower costs of interest-bearing liabilities. A significant $12.7 million charge-off related to cannabis loans affected net charge-offs, while the company maintained a focus on asset quality and disciplined loan loss provisioning. No specific guidance for future quarters was provided.